The Double Life of IP: How Multinationals Shift Profits Through Accounting

Intellectual property (IP) drives vast profits worldwide—but it also has a hidden financial “double life.”

Multi-jurisdictional corporate groups (MJGs), particularly those in big tech and big pharma, routinely leverage IP’s unique characteristics to slash their global tax bills. Here’s how the same intellectual property asset can simultaneously exist as two separate financial entities within a single corporate group.

One IP, Two Balance Sheets

Imagine a U.S. multinational develops groundbreaking software technology or a new pharmaceutical patent—such as those created by companies like Microsoft or Pfizer. This innovation is recorded as a valuable intangible asset on the U.S. parent company’s balance sheet, clearly reflecting its full ownership, control, and rights over the IP.

Next, the company establishes a subsidiary in Ireland—a jurisdiction celebrated for its advantageous corporate tax rates and generous accounting treatment of intangible assets. While the Irish subsidiary does not legally own the IP itself, it secures a licence agreement with the U.S. parent company granting it exclusive economic rights to exploit and sublicense the technology internationally.

Here’s the crucial twist: the licence agreement itself becomes a valuable intangible asset on the Irish subsidiary’s balance sheet. This effectively means the same IP is recorded twice—first as a fully owned intangible asset on the U.S. parent’s balance sheet, and second, separately, as licensed economic rights on the Irish subsidiary’s balance sheet.

The Magic of Royalty Payments

The Irish subsidiary then sublicenses this IP to affiliates located in higher-tax jurisdictions worldwide. These subsidiaries pay substantial royalties back to the Irish entity, allowing them to deduct these payments as business expenses, thereby significantly reducing their taxable profits locally.

In turn, the Irish subsidiary pays only modest royalties back to the U.S. parent, ensuring the majority of global profits remain in Ireland, benefiting from its low-tax environment. This arrangement is central to the accounting—not merely tax-driven—strategies commonly employed by IP-rich U.S. multinationals in Ireland.

Why Does This Matter?

This strategic setup shifts profits from high-tax countries to low-tax jurisdictions, dramatically lowering the group’s overall global tax rate. While entirely legal, it fuels ongoing controversy and debate, raising complex questions about corporate accountability in global taxation.

The dual-accounting existence of IP—as both owned outright and separately licensed—is critical to understanding how multinationals manage and minimise their global tax obligations. Recognising this double life sheds essential light on the role of accounting power in global profit-shifting.

3 responses to “The Double Life of IP: How Multinationals Shift Profits Through Accounting”

  1. […] did it work? Through transfer pricing. AbbVie assigned ownership of the license to its most valuable IP assets—its drug patents—to Irish subsidiaries. These Irish entities […]

  2. […] dual treatment of intellectual property is central to understanding how profit shifting operates in modern global capitalism. The rights to […]

  3. […] boom is driven not just by tax rates but by accounting design. Intellectual property has a financial “double life.” A single piece of IP—say, a software platform or pharmaceutical formula—can appear on two […]

Leave a Reply

Discover more from Democracy Challenged

Subscribe now to keep reading and get access to the full archive.

Continue reading